October 2017 Issue of MMM
October 2017 cover
The answer: it depends on what phase the trial is in.
Career and Salary Survey
Salaries are up — by a lot — and marketers are enthusiastic about their career prospects.
Now that Facebook, Apple, and Google have set their sights on healthcare, agencies find themselves under pressure from yet another flank.
Management turnover has brought the opportunity to keep up the pressure.
The best marketers possess a mix of scientific know-how, digital dexterity, and unflappability. To keep them, agencies need to revise their thinking and tactics.
The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.
The successes of these pharma execs show that there's no one path to professional bliss.
The agency appointed Sonja Foster-Storch, previously president of McCann Echo, to fill a role that has been vacant since 2016.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
How can marketers ensure that patients and physicians aren't overwhelmed by these tactics?
The e-giant is reportedly doing everything from starting secret labs and online pharmacies to redefining the hospital experience and democratizing health data.
Every agency in the biz claims to have a "unique" culture and one that fuels a great deal of its success.
The copywriter and the art director come together to inform, spark hope, and create a path forward.
At Work With
A mentor once told him to keep learning and stay out of his comfort zone.
AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.